Narrative review explores macrophage reprogramming for liver fibrosis and MASH
Scientists explore new ways to reprogram liver cells to heal damaged tissue and stop scarring
This narrative review summarizes macrophage reprogramming strategies for liver fibrosis and MASH. Approaches include gene modulation, pharma…
A recent review looks at fresh methods to change how liver immune cells behave. These changes could help heal liver scarring and improve hea…
Systematic review and meta-analysis evaluates ML and DL models for diagnosing MASH and fibrosis
AI models help doctors spot liver disease with high accuracy
This systematic review and meta-analysis of 106 studies assessed machine learning (ML) and deep learning (DL) models for diagnosing metaboli…
New computer tools can diagnose fatty liver disease and scarring with impressive accuracy. This review analyzed data from many studies to se…
Review of liver disease immunomodulation strategies notes precision over broad suppression
Your Liver's Immune Cells Play Both Hero and Villain at Once
This narrative review examines immunomodulation approaches for liver diseases, including acute liver injury, HBV infection, MASLD/MASH, fibr…
Liver immune cells can both damage and repair your organ at the same time, a discovery that could unlock new precision treatments for hepati…
PON1 genetic variants rs2057681 and rs854572 modulate PONase activity and dysmetabolic risk in MASLD
Your Liver's Hidden Genetic Shield
This cohort study of 922 Portuguese individuals from the PREVADIAB2 cohort examined associations between PON1 genetic variants and metabolic…
Your specific DNA pattern for a liver enzyme predicts diabetes and liver scarring risk better than simple blood tests alone.
Review of bile acid homeostasis regulation in liver disease and cancer
Review of bile acid regulation for liver disease conditions shows limited evidence
This narrative review examines the regulation of bile acids homeostasis in conditions including cholestasis, hepatic fibrosis, cirrhosis, he…
Bile acid imbalance drives liver disease, but this review found no data proving that regulating it safely treats conditions like cirrhosis o…
Hospitalized malignant neoplasm patients show high comorbidity burden and distinct disease patterns across 163 Chinese hospitals
Hospitalized cancer patients in China often have other serious health conditions
This retrospective cohort study examined 107,029 hospitalized patients with malignant neoplasms across 163 hospitals in Zhanjiang, China.
Hospitalized cancer patients in China often face five other serious health conditions, with rural residents, men, and those aged 65 or older…
Perspective reviews emerging antifibrotic therapies for metabolic dysfunction-associated steatohepatitis
Could new drugs finally treat the liver scarring of MASH?
A perspective article reviews emerging antifibrotic therapies for metabolic dysfunction-associated steatohepatitis (MASH), including metabol…
New metabolic drugs and direct liver therapies offer fresh hope for reversing the scarring that leads to dangerous cirrhosis in MASH patient…
Research across Cirrhosis
Related studies from across the Cirrhosis family.
Hepatologist-led palliative care matches specialist care for cirrhosis and cancer patients
Trained liver doctors provided care that matched specialists for patients with serious liver disease
A US trial found hepatologist-delivered palliative care noninferior to specialist care for improving quality of life in advanced liver disea…
Patients with advanced liver disease saw similar quality of life improvements when cared for by trained liver doctors versus specialists. Bo…
Narrative review on sepsis in end-stage liver disease and acute-on-chronic liver failure
Patients with severe liver disease and sepsis face high risks and need careful care plans
This narrative review synthesizes evidence on sepsis in patients with end-stage liver disease and acute-on-chronic liver failure. It describ…
People with advanced liver sickness and sepsis often have weak immune systems and get hard-to-treat infections. Doctors say new treatments l…
L-taurine shows no overall fatigue benefit in decompensated cirrhosis but may help non-anemic patients
Taurine for cirrhosis fatigue fails overall but helps one group
This randomized controlled trial in 220 adults with decompensated cirrhosis found no significant difference in fatigue scores with L-taurine…
Taurine did not reduce fatigue in most cirrhosis patients, but those without anemia saw meaningful improvement, suggesting a targeted approa…
Review of scRNA-seq applications in non-alcoholic fatty liver disease and hepatocellular carcinoma research
New sequencing tools map liver disease across many species
This narrative review examines the use of single-cell and single-nucleus RNA sequencing in models of non-alcoholic fatty liver disease, fibr…
Scientists used advanced sequencing to study liver disease in humans and animals. This review maps how the disease changes at a cellular lev…
Influenza vaccine induces stronger immune responses in liver cirrhosis patients
Flu Shot Works Better in Advanced Liver Disease
This prospective observational study found that patients with liver cirrhosis mount stronger humoral and cell-mediated immune responses to t…
You’re living with cirrhosis. Every cold feels dangerous.
Nurse-assisted outpatient follow-up reduces 30-day readmissions but not mortality in decompensated cirrhosis
Nurse Care Cuts Hospital Returns for Liver Patients
A meta-analysis of 668 patients with decompensated liver cirrhosis found nurse-assisted outpatient follow-up significantly reduced 30-day re…
Adding nurses to liver care teams significantly cuts 30-day hospital readmissions and improves outcomes for patients with advanced liver dis…
First-in-human study finds VS-01 generally well tolerated in decompensated cirrhosis with ascites
Early safety study of VS-01 infusion in 12 patients with advanced liver disease
This phase 1b, open-label, non-randomized study in 12 patients with decompensated cirrhosis, ascites, and covert hepatic encephalopathy foun…
A new liver treatment called VS-01 was safe for patients with advanced disease, causing mostly mild stomach issues in an early study of 12 p…
Novel nomogram predicts long-term survival after TIPS in decompensated cirrhosis
Can we better predict survival for cirrhosis patients getting TIPS treatment?
A retrospective single-center cohort study of 409 patients with decompensated cirrhosis undergoing first TIPS developed and validated a nomo…
A new prediction tool outperforms standard scores at estimating how long patients with advanced liver disease will survive after a major shu…
Phase 1/2a trial tests oral idebenone safety in adults with NASH and fibrosis
Can an oral drug help people with fatty liver disease? Early safety study begins
A randomized, double-blinded, placebo-controlled, single-center phase 1/2a study enrolled 53 adults with NASH and stage 1-3 fibrosis to asse…
A new oral drug for fatty liver disease has finished its early safety study, with results expected soon to show if it helps stop scarring.
Questions about Liver Fibrosis
Are there new immunomodulation strategies to treat liver fibrosis?
Yes, new immunomodulation strategies for liver fibrosis focus on reprogramming macrophages, targeting specific immune subsets, and using metabolic therapies like GLP-1 analogues and THRβ activators.
Full answer →Can nanotechnology be used to treat liver fibrosis?
Nanotechnology shows promise for treating liver fibrosis by delivering drugs directly to liver cells, improving how treatments work, and reducing side effects compared to traditional methods.
Full answer →What are the new antifibrotic therapies for liver fibrosis?
New antifibrotic therapies focus on reprogramming immune cells like macrophages and using metabolic drugs that reduce liver fat, rather than just targeting scar tissue directly.
Full answer →Do PON1 genetic variants affect my risk for liver fibrosis?
Specific genetic variants in the PON1 gene can change how well the enzyme works, which directly influences a person's risk for developing liver fibrosis and related metabolic issues.
Full answer →How do machine learning models help diagnose liver fibrosis?
Machine learning models analyze patient data to predict liver fibrosis with moderate accuracy, often outperforming traditional tests like FIB-4, but they are not yet standard in clinical practice.
Full answer →Can gene modulation help treat liver fibrosis and MASH?
Yes, gene modulation is a promising experimental approach for liver fibrosis and MASH, with several strategies showing preclinical success, though human treatments are not yet available.
Full answer →